Pfizer's Prevnar 13 vaccine slashed the number of pneumonia cases in older adults, according to details from a new study that could add up to $1 billion to its global sales.
written on 13.03.2014
Analysts see $1.5B boost for Pfizer on 'better than expected' Prevnar 13 data
